Cargando…
Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326930/ https://www.ncbi.nlm.nih.gov/pubmed/37420163 http://dx.doi.org/10.1186/s12885-023-11135-3 |
| _version_ | 1785069527000678400 |
|---|---|
| author | Xu, Yu-Yin Chen, Li Wang, Gui-Lan Zhou, Jia-Ming Zhang, Yi-Xin Wei, Yin-Ze Zhu, Yuan-Yuan Qin, Jing |
| author_facet | Xu, Yu-Yin Chen, Li Wang, Gui-Lan Zhou, Jia-Ming Zhang, Yi-Xin Wei, Yin-Ze Zhu, Yuan-Yuan Qin, Jing |
| author_sort | Xu, Yu-Yin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10326930 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103269302023-07-08 Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo Xu, Yu-Yin Chen, Li Wang, Gui-Lan Zhou, Jia-Ming Zhang, Yi-Xin Wei, Yin-Ze Zhu, Yuan-Yuan Qin, Jing BMC Cancer Retraction Note BioMed Central 2023-07-07 /pmc/articles/PMC10326930/ /pubmed/37420163 http://dx.doi.org/10.1186/s12885-023-11135-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Retraction Note Xu, Yu-Yin Chen, Li Wang, Gui-Lan Zhou, Jia-Ming Zhang, Yi-Xin Wei, Yin-Ze Zhu, Yuan-Yuan Qin, Jing Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo |
| title | Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo |
| title_full | Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo |
| title_fullStr | Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo |
| title_full_unstemmed | Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo |
| title_short | Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo |
| title_sort | retraction note: a synthetic dsrna, as a tlr3 pathwaysynergist, combined with sorafenib suppresses hcc in vitro and in vivo |
| topic | Retraction Note |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326930/ https://www.ncbi.nlm.nih.gov/pubmed/37420163 http://dx.doi.org/10.1186/s12885-023-11135-3 |
| work_keys_str_mv | AT xuyuyin retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo AT chenli retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo AT wangguilan retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo AT zhoujiaming retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo AT zhangyixin retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo AT weiyinze retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo AT zhuyuanyuan retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo AT qinjing retractionnoteasyntheticdsrnaasatlr3pathwaysynergistcombinedwithsorafenibsuppresseshccinvitroandinvivo |